No Detail Found!

Effectiveness and Safety of Enoxaparin as Anticoagulant In Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Coronary Artery Disease: Five-years Experience of a Single Center.

Author(s)
Muhammad Asghar Khan Department of Cardiology, Hayatabad Medical Complex, Peshawar – Pakistan
Muhammad Abdul Rauf Department of Cardiology, Hayatabad Medical Complex, Peshawar – Pakistan
Mahmoodul Hassan Department of Cardiology, Hayatabad Medical Complex, Peshawar – Pakistan
Imran Khan Department of Cardiology, Hayatabad Medical Complex, Peshawar – Pakistan
Raufillah Jan Department of Cardiology, Hayatabad Medical Complex, Peshawar – Pakistan
Zahid Aslam Awan Department of Cardiology, Hayatabad Medical Complex, Peshawar – Pakistan
Abstract
Objective: To determine the effectiveness and safety of enoxaparin as anticoagulant in patients undergoing elective percutaneous coronary intervention for stable coronary artery disease. Methodology: This study was conducted at the Department of Department of Cardiology, Hayat Abad Medical Complex, Peshawar, from March 2013 to December 2017. All patients who underwent elective percutaneous coronary intervention (PCI) for stable coronary artery disease were included in the study. We retrospectively analysed our data for short term outcome of efficacy and safety with use of enoxaparin as procedural anticoagulant. The dose of enoxaparin used was 0.75-1mg/kg. Sheath removal with manual compression haemostasis was performed 6 hours after the femoral route and within first hour after the radial procedure. Data were analysed by SPSS version 23. Results: A total of 3190 elective PCIs with enoxaparin as anticoagulant were performed in the study period. Mean age of the patients was 57.48 ±6.9 years and 70% were males. Among the efficacy end points, major adverse cardiovascular events occurred in 1.4%. Mortality of any cause was 0.34% in the total patients studied. Urgent repeat revascularization for acute stent thrombosis was performed in 0.4% of patients. Acute MI and ischemic strokes occurred in 0.50% and 0.15% of patients respectively. Among the safety end points, major bleeding occurred in 0.37% of patients. Intracerebral bleeds and coronary perforations were 0.06% each. Minor bleeding that did not cause any significant morbidity were in 2.85% patients. Conclusion: Enoxaparin in a weight based regimen can be used effectively and safely for percutaneous coronary interventions for stable coronary artery disease.
Publication Details
Page(s) 144-149
DOI DOI not available
Published Journal: Journal of Postgraduate Medical Institute, Volume: 32, Issue: 2, Year: 2018

Request the full text from PASTIC

References
ZeymerU,RaoSV,MontalescotG.,,2016,Anticoagulation in coronary intervention,Eur Heart J,37,3376-85
SmithSC,FeldmanTE,HirshfeldJW,JacobsAK,KernMJ,KingSB,,2006,update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention),J Am Coll Cardiol,47,e1-121
WijnsW,KolhP,DanchinN,Di MarioC,FalkV,FolliguetT,,2010,Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),Eur Heart J,31,2501-55
StegPG,JollySS,MehtaSR,AfzalR,XavierD,RupprechtHJ,,2010,Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial,J Am Med Assoc,304,1339-49
BrenerSJ,MoliternoDJ,LincoffAM,SteinhublSR,WolskiKE,TopolEJ,,2004,Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention,Circulation,110,994-8
De CaterinaR,HustedS,WallentinL,AgnelliG,BachmannF,BaigentC,,2007,Anticoagulants in heart disease: current status and perspectives,Eur Heart J,28,880-913
WindeckerS,KolhP,AlfonsoF,ColletJP,CremerJ,FalkV,,2014,ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).,,,-
AlamS,NaqviS,GauharS. Product,Management,,2009,Efficacy Evaluation of an Anti-Coagulant Enoxapari (Clexane,Pakistan; Oman Med J,24,264-8
SilvainJ,BeyguiF,AnkriA,Bellemain-AppaixA,PenaA,BarthelemyO,,2010,Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test,J Am Coll Cardiol,55,617-25
MontalescotG,ColletJP,TanguyML,AnkriA,PayotL,DumaineR,,2004,Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin,Circulation,110,392-8
MontalescotG,ZeymerU,SilvainJ,BoulangerB,CohenM,GoldsteinP,,2011,Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL Trial,Lancet,378,693-703
DiezJG,,2008,Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention,J Invasive Cardiol,20,482-9
MarsoSP,AminAP,HouseJA,KennedyKF,SpertusJA,RaoSV,,2010,Association Between Use of Bleeding Avoidance Strategies and Risk of Periprocedural Bleeding Among Patients Undergoing Percutaneous Coronary Intervention,J Am Med Assoc,303,2156-64
ChhatriwallaAK,AminAP,KennedyKF,HouseJA,CohenDJ,RaoSV,,2013,Association Between Bleeding Events and In-hospital Mortality After Percutaneous Coronary Intervention,J Am Med Assoc,309,1022-9
YusafS,HawkenS,OupuuS,DansT,AvezumA,LanasF,,2004,Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case control study,Lancet,364,937-52
KhanMA,HassanM,HafizullahM.,,2006,Coronary artery disease, is it more frequently affecting younger age group and women?,Pak Heart J,39,17-21
0

Citations

0

Downloads

58

Views